Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings
Pacira BioSciences, Inc. (PCRX)
Last pacira biosciences, inc. earnings: 2/20 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.pacira.com
Company Research
Source: GlobeNewswire
-- Final CMS rule concludes iovera is a qualifying device for separate payment under the NOPAIN Act -- -- Beginning January 1, 2025, providers can receive additional Medicare payment when they use EXPAREL or iovera° via product-specific reimbursement codes -- PARSIPPANY, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NSDQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced that the Centers for Medicare and Medicaid Services (CMS) issued its final Medicare Hospital Outpatient Prospective Payment System (OPPS) and Medicare Ambulatory Surgical Center (ASC) Payment System rule for 2025, which implements the Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act that mandated separate Medicare payment for qualifying non-opioid drugs and devices. In the final rule, CMS confirmed that both EXPAREL® (bupivacaine liposome injectable suspension) and iovera° qualify as eligible non-o
Show less
Read more
Impact Snapshot
Event Time:
PCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCRX alerts
High impacting Pacira BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
PCRX
News
- Levi & Korsinsky Announces an Investigation on Behalf of Pacira BioSciences, Inc. (PCRX) Shareholders Who May Have Been Affected by FraudAccesswire
- Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee [Yahoo! Finance]Yahoo! Finance
- Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the KneeGlobeNewswire
- Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Barclays PLC from $25.00 to $17.00. They now have an "equal weight" rating on the stock.MarketBeat
- Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare ConferencesGlobeNewswire
PCRX
Earnings
- 11/6/24 - Beat
PCRX
Sec Filings
- 11/6/24 - Form 10-Q
- 11/6/24 - Form 8-K
- 11/5/24 - Form 4
- PCRX's page on the SEC website